Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Novocure’s Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
(NASDAQ: NVCR) Delayed: 16.72 +0.50 (3.08%)
Previous Close $16.22    52 Week High $28.95 
Open $16.58    52 Week Low $5.95 
Day High $16.99    P/E N/A 
Day Low $16.13    EPS $0.00 
Volume 1,482,998